Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  8,738 results for ""Immune Checkpoint Inhibitors""

Your Filters

Publisher : biomed central
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.

  • Authors : Wei J; Department of Medical Oncology, Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, China.; Li W

Subjects: Biomarkers, Tumor*/Biomarkers, Tumor*/Biomarkers, Tumor*/analysis ; Biomarkers, Tumor*/Biomarkers, Tumor*/Biomarkers, Tumor*/immunology ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use

  • Source: Molecular cancer [Mol Cancer] 2024 Dec 26; Vol. 23 (1), pp. 279. Date of Electronic Publication: 2024 Dec 26.Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium:

Record details

Connect Read More Add to Saved list
×
Academic Journal

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

  • Authors : Chen Y; Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong-An Road, Shanghai, 200032, China.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/immunology ; Quinolines*/Quinolines*/Quinolines*/therapeutic use

  • Source: Journal of hematology & oncology [J Hematol Oncol] 2024 Dec 21; Vol. 17 (1), pp. 130. Date of Electronic Publication: 2024 Dec 21.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

  • Authors : Zhang X; Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.; Institute of Marine Science and Technology, Shandong University, Qingdao, China.

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use ; Biomarkers, Tumor*/Biomarkers, Tumor*/Biomarkers, Tumor*/genetics

  • Source: BMC medicine [BMC Med] 2024 Dec 18; Vol. 22 (1), pp. 585. Date of Electronic Publication: 2024 Dec 18.Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis.

Subjects: B7-H1 Antigen*/B7-H1 Antigen*/B7-H1 Antigen*/antagonists & inhibitors ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/adverse effects

  • Source: BMC cancer [BMC Cancer] 2024 Nov 05; Vol. 24 (1), pp. 1353. Date of Electronic Publication: 2024 Nov 05.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC.

  • Authors : Zhang J; Department of Urology, Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China.; Peng Q

Subjects: Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/genetics ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/immunology

  • Source: Journal of translational medicine [J Transl Med] 2024 Dec 30; Vol. 22 (1), pp. 1157. Date of Electronic Publication: 2024 Dec 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.

  • Authors : Pan C; Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, WA, USA.; Ng K

Subjects: Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/blood ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/drug therapy

  • Source: BMC cancer [BMC Cancer] 2024 Nov 15; Vol. 24 (1), pp. 1406. Date of Electronic Publication: 2024 Nov 15.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective.

  • Authors : Zietse M; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. .; Malmberg R

Subjects: Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/economics ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/administration & dosage ; Infusion Pumps*/Infusion Pumps*/Infusion Pumps*/economics

  • Source: BMC health services research [BMC Health Serv Res] 2024 Oct 31; Vol. 24 (1), pp. 1322. Date of Electronic Publication: 2024 Oct 31.Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis.

  • Authors : Huang D; Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China. .; Li S

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Endometrial Neoplasms*/Endometrial Neoplasms*/Endometrial Neoplasms*/drug therapy

  • Source: BMC cancer [BMC Cancer] 2024 Oct 21; Vol. 24 (1), pp. 1298. Date of Electronic Publication: 2024 Oct 21.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study.

  • Authors : Feng L; Department of Gynecology, The First Affiliated Hospital of Xingtai Medical College, Xingtai, 054000, China.; Shi Q

Subjects: Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/drug therapy ; Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/mortality ; Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/pathology

  • Source: BMC cancer [BMC Cancer] 2024 Oct 11; Vol. 24 (1), pp. 1267. Date of Electronic Publication: 2024 Oct 11.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors.

  • Authors : Zhang J; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.; Xie Y

Subjects: Venous Thromboembolism*/Venous Thromboembolism*/Venous Thromboembolism*/epidemiology ; Venous Thromboembolism*/Venous Thromboembolism*/Venous Thromboembolism*/chemically induced ; Lung Neoplasms*/Lung Neoplasms*/Lung Neoplasms*/drug therapy

  • Source: BMC pulmonary medicine [BMC Pulm Med] 2024 Oct 10; Vol. 24 (1), pp. 507. Date of Electronic Publication: 2024 Oct 10.Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  8,738 results for ""Immune Checkpoint Inhibitors""